Could a common bile acid pill shield kidneys during cancer surgery?
NCT ID NCT07672860
First seen Jun 29, 2026 · Last updated Jun 30, 2026 · Updated 1 time
Summary
This trial investigates whether ursodeoxycholic acid (UDCA), a bile acid medication, can protect kidney function in adults undergoing partial nephrectomy for kidney cancer. During surgery, blood flow to the kidney is temporarily stopped, which can cause injury. Participants take UDCA or a placebo from two days before surgery to five days after. The study measures acute kidney injury rates and kidney function changes, aiming to see if UDCA reduces damage.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Ursodeoxycholic acid (UDCA)
What this could lead to
If it works, UDCA could become a simple, safe way to protect kidney function during kidney cancer surgery, reducing the risk of acute kidney injury.
What could go wrong
This is a small, early-phase trial. UDCA may not provide significant protection, and results may not apply to all patients or surgeries.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KIDNEY CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing
RECRUITINGNanjing, Jiangsu, 210000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••